Ionis

News

Novartis licenses lipoprotein-lowering CVD drug

Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment to reduce the risk of cardiovascular disease in people living with elev

News

Eyeing Novartis deal, Akcea trumpets lipoprotein drug data

Ionis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with cardiovascular disease that it hopes will entice Novartis into a licensing deal.

News

Alnylam's Onpattro is first ever FDA-approved RNAi drug

Onpattro will cost $450,000 a year

News

Alnylam hopes for 2018 filing for RNAi liver disease drug

Alnylam is hoping to file a second RNA interference (RNAi) drug with the FDA by the end of 2018 after unveiling encouraging early-stage data for givosiran in a rare liver disease.<

News

Alnylam beats Ionis in RNA drug battle

Alnylam and Sanofi have revealed full phase 3 data on their RNA interference (RNAi) drug patisiran, soundly beating a rival candidate from Ionis, inotersen.

News